The steroid sulfatase or steryl sulfatase is a microsomal enzyme widely distributed in human tissues that catalyzes the hydrolysis of sulfated 3-hydroxy steroids to the corresponding free active 3-hydroxy steroids. Since androgens and estrogens may be synthesized inside the cancerous cells starting from dehydroepiandrosterone sulfate (DHEAS) and estrone sulfate (E(1)S) available in blood circulation, the use of therapeutic agents that inhibit steroid sulfatase activity may be a rewarding approach to the treatment of androgeno-sensitive and estrogeno-sensitive diseases. In the present study, we report the chemical synthesis and biological evaluation of a new family of steroid sulfatase inhibitors. The inhibitors were designed by adding an alkyl, a phenyl, a benzyl, or a benzyl substituted at position 17alpha of estradiol (E(2)), a C18-steroid, and enzymatic assays were performed using the steroid sulfatase of homogenized JEG-3 cells or transfected in HEK-293 cells. We observed that a hydrophobic substituent induces powerful inhibition of steroid sulfatase while a hydrophilic one was weak. Although a hydrophobic group at the 17alpha-position increased the inhibitory activity, the steric factors contribute to the opposite effect. As exemplified by 17alpha-decyl-E(2) and 17alpha-dodecyl-E(2), a long flexible side chain prevents adequate fitting into the enzyme catalytic site, thus decreasing capacity to inhibit the steroid sulfatase activity. In the alkyl series, the best compromise between hydrophobicity and steric hindrance was obtained with the octyl group (IC(50) = 440 nM), but judicious branching of side chain could improve this further. Benzyl substituted derivatives of estradiol were better inhibitors than alkyl analogues. Among the series of 17alpha-(benzyl substituted)-E(2) derivatives studied, the 3'-bromobenzyl, 4'-tert-butylbenzyl, 4'-butylbenzyl, and 4'-benzyloxybenzyl groups provided the most potent inhibition of steroid sulfatase transformation of E(1)S into E(1) (IC(50) = 24, 28, 25, and 22 nM, respectively). As an example, the tert-butylbenzyl group increases the ability of the E(2) nucleus to inhibit the steroid sulfatase by 3000-fold, and it also inhibits similarly the steroid sulfatase transformations of both natural substrates, E(1)S and DHEAS. Interestingly, the newly reported family of steroid sulfatase inhibitors acts by a reversible mechanism of action that is different from the irreversible mechanism of the known inhibitor estrone sulfamate (EMATE).

译文

:类固醇硫酸酯酶或固醇硫酸酯酶是广泛分布于人体组织中的微粒体酶,可催化硫酸化的3-羟基类固醇水解为相应的游离活性3-羟基类固醇。由于雄激素和雌激素可能是从血液中可用的脱氢表雄酮硫酸盐(DHEAS)和硫酸雌酮(E(1)S)开始在癌细胞内合成的,因此使用抑制类固醇硫酸酯酶活性的治疗剂可能是一种有益的方法。雄激素敏感性和雌激素敏感性疾病的治疗。在本研究中,我们报告了甾族硫酸酯酶抑制剂新家族的化学合成和生物学评估。通过添加在雌二醇(E(2))的17α位上取代的烷基,苯基,苄基或苄基,C18-类固醇来设计抑制剂,并使用均质的JEG-3的类固醇硫酸酯酶进行酶促测定细胞或转染到HEK-293细胞中。我们观察到,疏水取代基可强烈抑制类固醇硫酸酯酶,而亲水取代基则较弱。尽管在17α-位的疏水基团增加了抑制活性,但位阻因素却起到了相反的作用。如17alpha-癸基-E(2)和17alpha-十二烷基-E(2)所示,较长的柔性侧链会阻止酶催化位点的适当装配,从而降低了抑制类固醇硫酸酯酶活性的能力。在烷基系列中,疏水性和空间位阻之间的最佳折衷是使用辛基(IC(50)= 440 nM),但是明智的侧链支化可以进一步改善这一点。雌二醇的苄基取代衍生物是比烷基类似物更好的抑制剂。在研究的一系列17α-(苄基取代)-E(2)衍生物中,3'-溴苄基,4'-叔丁基苄基,4'-丁基苄基和4'-苄氧基苄基提供了对甾族硫酸酯酶的最有效抑制作用E(1)S转换为E(1)(IC(50)分别为24、28、25和22 nM)。例如,叔丁基苄基可将E(2)核抑制类固醇硫酸酯酶的能力提高3000倍,并且还可以类似地抑制两种天然底物E(1)S和DHEAS的类固醇硫酸酯酶转化。有趣的是,新报道的甾族硫酸酯酶抑制剂家族通过可逆的作用机理起作用,该作用机理不同于已知的抑制剂氨基磺酸雌酮(EMATE)的不可逆机理。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录